In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response
Authors
Keywords
-
Journal
ADVANCED MATERIALS
Volume -, Issue -, Pages 2100628
Publisher
Wiley
Online
2021-06-12
DOI
10.1002/adma.202100628
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics
- (2020) Colin G. Buss et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy
- (2019) Maxim Shevtsov et al. Frontiers in Oncology
- Systematic investigation of in vitro and in vivo safety, toxicity and degradation of mesoporous silica nanoparticles synthesized using commercial sodium silicate
- (2019) Dhaval Bhavsar et al. MICROPOROUS AND MESOPOROUS MATERIALS
- Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators
- (2019) João Conniot et al. Nature Nanotechnology
- siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion
- (2019) Worapol Ngamcherdtrakul et al. Translational Research
- Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery
- (2018) Worapol Ngamcherdtrakul et al. International Journal of Nanomedicine
- Combination treatment of VLA-4 targeted radionuclide therapy and immunotherapy in a mouse model of melanoma
- (2018) Jaeyeon Choi et al. JOURNAL OF NUCLEAR MEDICINE
- Prognostic value of intra-tumoral CD8+ /FoxP3+ lymphocyte ratio in patients with resected colorectal cancer liver metastasis
- (2018) Kostandinos Sideras et al. JOURNAL OF SURGICAL ONCOLOGY
- MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2018) Brigitte Dreno et al. LANCET ONCOLOGY
- Signal management in pharmacovigilance and human risk assessment of CpG 7909, integrating embryo-fetal and post-natal developmental toxicity studies in rats and rabbits
- (2018) Frédérique Delannois et al. REPRODUCTIVE TOXICOLOGY
- In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree
- (2018) Mee Rie Sheen et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- Mechanisms of Resistance to Immune Checkpoint Blockade
- (2018) David Liu et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
- (2018) Antoni Ribas et al. Cancer Discovery
- Defining Memory CD8 T Cell
- (2018) Matthew D. Martin et al. Frontiers in Immunology
- Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy
- (2017) Yuchen Fan et al. NANO LETTERS
- Quantitative determination of a siRNA (AD00370) in rat plasma using peptide nucleic acid probe and HPLC with fluorescence detection
- (2017) Qingguo Tian et al. Bioanalysis
- Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
- (2017) Chunying Song et al. Cancer Discovery
- Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer
- (2017) Anthony S. Malamas et al. Oncotarget
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model
- (2016) Marie Jordan et al. CANCER LETTERS
- Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment
- (2016) Worapol Ngamcherdtrakul et al. CANCER TREATMENT REVIEWS
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- Poly-functional and long-lasting anticancer immune response elicited by a safe attenuated Pseudomonas aeruginosa vector for antigens delivery
- (2016) Xavier Chauchet et al. Molecular Therapy-Oncolytics
- Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
- (2016) Hasan Rehman et al. Journal for ImmunoTherapy of Cancer
- Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+Breast Cancer
- (2015) Worapol Ngamcherdtrakul et al. ADVANCED FUNCTIONAL MATERIALS
- Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis
- (2015) Jingga Morry et al. BIOMATERIALS
- STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells
- (2015) Heng Yang et al. CANCER RESEARCH
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Stemming the Rising Incidence of Melanoma: Calling Prevention to Action
- (2015) Jeffrey E. Gershenwald et al. JNCI-Journal of the National Cancer Institute
- Stemming the Rising Incidence of Melanoma: Calling Prevention to Action
- (2015) Jeffrey E. Gershenwald et al. JNCI-Journal of the National Cancer Institute
- The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma
- (2014) Pallab Pradhan et al. BIOMATERIALS
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Routes of Delivery for CpG and Anti-CD137 for the Treatment of Orthotopic Kidney Tumors in Mice
- (2014) Jennifer A. Westwood et al. PLoS One
- Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
- (2014) E. Phillips et al. Science Translational Medicine
- Immune checkpoints in cancer clinical trials
- (2014) Elad Sharon et al. Chinese Journal of Cancer
- Mesoporous Silica Nanoparticle Nanocarriers: Biofunctionality and Biocompatibility
- (2013) Derrick Tarn et al. ACCOUNTS OF CHEMICAL RESEARCH
- Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells
- (2013) Min Beom Heo et al. BIOMATERIALS
- Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
- (2013) M Millward et al. BRITISH JOURNAL OF CANCER
- Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
- (2013) H Inoue et al. CELL DEATH AND DIFFERENTIATION
- Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells
- (2012) Y. Shirota et al. JOURNAL OF IMMUNOLOGY
- Dissolution from inside: a unique degradation behaviour of core–shell magnetic mesoporous silica nanoparticles and the effect of polyethyleneimine coating
- (2012) Kaihua Chen et al. JOURNAL OF MATERIALS CHEMISTRY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
- (2011) C. Manegold et al. ANNALS OF ONCOLOGY
- CpG DNA as a vaccine adjuvant
- (2011) Christian Bode et al. Expert Review of Vaccines
- Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Vera Hirsh et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic Cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors
- (2011) T. Iwata-Kajihara et al. JOURNAL OF IMMUNOLOGY
- Biocompatibility, Biodistribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals
- (2010) Jie Lu et al. Small
- Toll-like Receptor 9 Activation of Signal Transducer and Activator of Transcription 3 Constrains Its Agonist-Based Immunotherapy
- (2009) M. Kortylewski et al. CANCER RESEARCH
- Optimized Systemic Dosing with CpG DNA Enhances Dendritic Cell-Mediated Rejection of a Poorly Immunogenic Mammary Tumor in BALB/c Mice
- (2009) Quan Cai et al. CTS-Clinical and Translational Science
- In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses
- (2009) Marcin Kortylewski et al. NATURE BIOTECHNOLOGY
- Understanding biophysicochemical interactions at the nano–bio interface
- (2009) Andre E. Nel et al. NATURE MATERIALS
- Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients
- (2008) B. G. Molenkamp et al. CLINICAL CANCER RESEARCH
- Role of Stat3 in suppressing anti-tumor immunity
- (2008) Marcin Kortylewski et al. CURRENT OPINION IN IMMUNOLOGY
- Oncolytic viruses: a novel form of immunotherapy
- (2008) Robin J Prestwich et al. Expert Review of Anticancer Therapy
- Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma
- (2008) Maja A. Hofmann et al. JOURNAL OF IMMUNOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started